Key Highlights
- 17.60% is the indicated pre-market decline for IRIDEX Corporation (NASDAQ:IRIX) on November 18, 2026, with shares indicated at USD 0.5765 against a calculated prior close of USD 0.70, a calculated move of -USD 0.12.
- 10.2 million USD was third quarter 2026 revenue, down 19% from USD 12.5 million a year earlier, as retina Revenue fell to USD 5.1 million from USD 6.7 million.
- 46 million USD to 48 million USD is the cut 2026 revenue guidance range, down from USD 51 million to USD 53 million, after weaker Demand in Europe and Asia and delayed orders.
- 3.7 million USD was cash on October 3, 2026, down USD 1.0 million in the quarter, against a USD 3.8 million convertible note and a third quarter net loss of USD 1.4 million, or USD 0.08 per share.
What Moved IRIDEX Corporation (NASDAQ:IRIX) in Pre-Market Trading on November 18, 2026 (-USD 0.12, -17.60%)
The indicated pre-market price of IRIDEX Corporation (NASDAQ:IRIX) is USD 0.5765 on Wednesday, November 18, 2026, a pre-market move of -17.60%. The calculated prior close, the November 17, 2026 regular-session close, is about USD 0.70 (USD 0.5765 divided by 0.824), and the calculated USD move is -USD 0.12 (price minus prior close). The decline follows the company release of third quarter 2026 results after the close on November 17, 2026. Pre-market Volume and a corroborated market Capitalization were not found.
The Rationale: Weaker Third Quarter Revenue and a Cut to 2026 Guidance for IRIDEX Corporation (NASDAQ:IRIX)
In the company release for the quarter ended October 3, 2026, total revenue was USD 10.2 million, down 19% from USD 12.5 million in the third quarter of 2025, a calculated fall of about USD 2.3 million. Retina products brought in USD 5.1 million against USD 6.7 million and the Cyclo G6 glaucoma family USD 3.2 million against USD 3.5 million. About 11,900 probes were sold against 14,900. Gross Margin improved to 42.4% from 32.1%, though the earlier period included a one-time write-off of about USD 0.8 million. Operating expenses were USD 5.5 million. Full-year revenue guidance was cut to USD 46 million to USD 48 million from USD 51 million to USD 53 million, excluding the Middle East. Chief Executive Officer Patrick Mercer said revenue came in below expectations because of weaker demand in Europe and Asia and order delays.
Valuation, Liquidity and Risks for IRIDEX Corporation (NASDAQ:IRIX)
The net loss was USD 1.4 million, or USD 0.08 per share, against USD 1.6 million, or USD 0.09 per share, a year earlier, a calculated 13.8% of revenue. Cash was USD 3.7 million on October 3, 2026, USD 1.0 million lower than on July 4, 2026, while a convertible note payable stood at USD 3.8 million. Calculated Gross Profit is about USD 4.3 million (42.4% of USD 10.2 million). A market capitalization could not be corroborated and is not stated. No Nasdaq deficiency notice was identified, but a price below USD 1.00 can lead to one if it persists.
Where Things Stand
IRIDEX Corporation (NASDAQ:IRIX) is indicated at USD 0.5765 in pre-market trading on November 18, 2026, down 17.60% from a calculated prior close of about USD 0.70. The move follows third quarter revenue of USD 10.2 million, a 19% decline, a net loss of USD 1.4 million and a cut in 2026 revenue guidance to USD 46 million to USD 48 million. Cash fell to USD 3.7 million against a USD 3.8 million convertible note. Pre-market quotes remain indicative until the open. This article is informational and is not Investment advice.






Please wait processing your request...